


AMENDMENTS TO THE CLAIMS

1. (original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, a compound of the general formula I:



wherein

Y is $-(CH_2)_m-$, $-CH(OH)-$ or $-C(=O)-$, and m is 0 - 3;

X is H, alkyl, $-CH_2OH-$, CH_2Oacyl or $-CH_2acyl$; and

R is H, a cation, alkyl or optionally substituted aryl; provided that:

- (a) When Y is $-(CH_2)_m-$, m=0, and R is H or cation, X is not CH_2Oacyl ; and
- (b) Said compound is not one of
 - (i) Phenyl 1,3-cyclic propanediol phosphate,
 - (ii) Phenyl 1,2-cyclic propanediol phosphate,
 - (iii) Cyclic dihydroxyacetone phosphate,
 - (iv) 1,3,-cyclic propanediol phosphate
 - (v) 1,3-cyclic glycerophosphate,
 - (vi) 1,2-cyclic propanediol phosphate,
 - (vii) 1,2-cyclic glycerophosphate.

2. (original) A pharmaceutical composition according to Claim 1, wherein said alkyl groups have 1-24

carbon atoms, said acyl groups are aliphatic saturated or unsaturated C₁ - C₂₄ acyl groups and said aryl group is a carbocyclic aryl group optionally substituted by C₁ - C₄ alkyl, halogen and/or hydroxy.

3. (original) A pharmaceutical composition according to Claim 2, wherein said acyl groups are derived from natural fatty acids.

4. (original) A pharmaceutical composition according to Claim 3, wherein said acyl group is a saturated aliphatic acyl group selected from acetyl, butyryl, caproyl, octanoyl, decanoyl, lauroyl, myristyl, palmitoyl and stearoyl, or an unsaturated aliphatic acyl group selected from palmitoleyl, oleyl, linoleyl, and ricinoleyl.

5. (original) A pharmaceutical composition according to any one of Claims 1-4, wherein said aryl group is phenyl.

6. (original) A pharmaceutical composition according to Claim 1, comprising phenyl 1,2-cyclic glycerophosphate.

7. (original) A pharmaceutical composition according to Claim 1, comprising 3-acyl 1,2-cyclic glycerophosphate.

8. (original) A pharmaceutical composition according to Claim 1, comprising cyclic oleyl lysophosphatidic acid.

9. (currently amended) A pharmaceutical composition according to Claim 1, comprising phenyl 1,3-cyclic glycerophosphate.

10. (currently amended) A pharmaceutical composition according to Claim 1, comprising phenyl cyclic dihydroxyacetone phosphate.

11. (original) A pharmaceutical composition for inducing phosphorylation in intracellular proteins of target cells comprising a pharmaceutically acceptable carrier and, as an active ingredient, a compound of general Formula I of Claim 1.

12. (original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, a compound of the general Formula I of Claim 1 for promotion of cell differentiation in target cells.

13. (currently amended) A pharmaceutical composition for the treatment of malignant diseases and disorders comprising a pharmaceutically acceptable carrier

and, as an active ingredient, a compound of the general Formula I of Claim 1 wherein

Y is $-(CH_2)_m-$, $-CH(OH)-$ or $-C(=O)-$, and m is 0 - 3;

X is H, alkyl, $-CH_2OH-$, CH_2Oacyl CH_2Oacyl or $-CH_2Oacyl$ CH_2Oacyl ; and

R is H, a cation, alkyl or optionally substituted aryl; provided that

when Y is $-(CH_2)_m-$, m=0, and R is H or cation, X is not CH_2Oacyl .

wherein said malignant disease or disorder is one against which said compound provides an effective treatment.

14. (original) A pharmaceutical composition according to Claim 13, wherein said malignant disorder is a blood malignancy.

15. (original) A pharmaceutical composition according to Claim 14, wherein said blood malignancy is leukemia.

16. (original) A pharmaceutical composition according to Claim 13, wherein said malignancy is breast cancer.

17. (original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an

active ingredient, a compound as defined in Claim 1, for induction of hormone-like signaling.


18. (currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, ~~a~~ as defined in Claim 13, for induction of hormone-like signaling wherein said hormone is selected from the group consisting of insulin, human growth hormone, and epidermal growth factor.

19. (original) A pharmaceutical composition according to Claim 17 or 18 wherein said hormone is insulin and the composition is for the treatment of non-insulin-dependent diabetes mellitus (non-IDDM type II diabetes).

20. (original) A pharmaceutical composition according to claim 17 or 18, wherein said hormone is human growth hormone (HGH) for the treatment of disorders in which HGH is involved.

21. (original) A pharmaceutical composition according to Claim 17 or 18, wherein said hormone is epidermal growth factor (EGF) for the treatment of disorders involving EGF.

22. (currently amended) A compound as defined in ~~claim 1 of the formula I~~



wherein

Y is $-(CH_2)_m-$, $-CH(OH)-$ or $-C(=O)-$, and m is 0 - 3;

X is H, alkyl, $-CH_2OH-$, CH_2Oacyl or $-CH_2acyl$; and

R is H, a cation, alkyl or optionally substituted aryl; provided that:

(a) when Y is $-(CH_2)_m-$, m=0, and R is H or cation, X is

not CH_2Oacyl ; and

(b) said compound is not one of

(i) Phenyl 1,3-cyclic propanediol phosphate,

(ii) Phenyl 1,2-cyclic propanediol phosphate,

(iii) Cyclic dihydroxyacetone phosphate,

(iv) 1,3,-cyclic propanediol phosphate


(v) 1,3-cyclic glycerophosphate,

(vi) 1,2-cyclic propanediol phosphate,

(vii) 1,2-cyclic glycerophosphate.

23. (currently amended) A compound of the formula

I:



wherein

Y is $-(CH_2)_m-$, $-CH(OH)-$ or $-C(=O)-$, and m is 0 - 3;

X is H, alkyl, $-CH_2OH-$, CH_2Oacyl or $-CH_2acyl$; and

R is H, a cation, alkyl or optionally substituted aryl;

provided that when Y is $-(CH_2)_m-$, m=0, and R is H or cation, X is not CH_2Oacyl ; as defined in Claim 1, with the exception of the following compounds:

- (i) compounds wherein Y is $-(CH_2)_m-$, m is 0, X is CH_3 , $-CH_2OH$ or CH_2Oacyl wherein acyl is a saturated carboxylic acyl with more than 12 carbon atoms, and R is H or a cation;
- (ii) compounds wherein Y is $-(CH_2)_m-$, m is 1, X is H and R is H, a cation or phenyl; and
- (iii) compounds wherein Y is $-CH(OH)-$, X is H and R is H, a cation or phenyl.

24. (previously amended) A compound according to Claim 22, selected from the group consisting of:

- (i) phenyl 1,2 cyclic glycerophosphate;
- (ii) phenyl cyclic dihydroxyacetone phosphate; and
- (iii) cyclic oleyl lysophosphatidic acid.

25. (currently amended) A method for treatment of disorders and diseases which can be treated by phosphorylation of intracellular proteins comprising administering to the individual in need a therapeutically effective amount of a compound as defined in Claim 13-23.

26. (currently amended) A method ~~according to~~ claim 25 for treatment of disorders and disease which can be treated by phosphorylation of intracellular proteins comprising administering to the individual in need a therapeutically effective amount of ~~wherein said compound is a~~ compound as defined in claim 1-22.

27. (currently amended) A method for the treatment of malignant diseases comprising administering to an individual in need a therapeutically effective amount of a compound as defined in claim 13-23.

28. (original) A method according to Claim 27, wherein said malignant disease or disorder is blood malignancy.

29. (original) A method according to Claim 28, wherein said blood malignancy is leukemia.

30. (original) A method according to Claim 27, wherein said malignant disease is breast cancer.

31. (currently amended) A method for the treatment of diseases involving hormone-like signaling comprising administering to an individual in need a therapeutically effective amount of a compound as defined in Claim ~~13~~ 23.

32. (currently amended) A method ~~according to~~ claim 31 for the treatment of diseases involving hormone-like signaling comprising administering to an individual in need a therapeutically effective amount of a compound wherein said compound is as defined in claim ~~1~~ 22.

33. (original) A method according to Claim 31 or 32, wherein said hormone is insulin and the disease treated is non-IDDM type II diabetes.

34. (original) A method according to Claim 31 or 32, wherein said hormone is human growth hormone (HGH) and the diseases treated are disorders in which HGH is involved.

35. (original) A method according to Claim 31 or 32, wherein said hormone is epidermal growth factor (EGF) and the diseases treated are disorders involving EGF.

36. (original) A method for detecting abnormal conditions of a tested cell comprising:

- (i) contacting the cells with cyclic glycerophosphates or their analogs (herein CGs) as defined in Claim 13;
- (ii) detecting the level of phosphorylation in intracellular proteins of the tested cells; and
- (iii) comparing said level of phosphorylation to the level of phosphorylation in intracellular proteins of normal cells following contact with said CGs, a level of phosphorylation differing from that detected in the normal cells indicating a high probability of abnormality in the tested cells.


37. (currently amended) A method ~~according to~~ for detecting abnormal conditions of a tested cell comprising:

- (i) contacting the cells with cyclic glycerophosphates or their analogs (herein CGs) as defined in Claim 13;
- (ii) detecting the level of phosphorylation in intracellular proteins of the tested cells; and
- (iii) comparing said level of phosphorylation to the level of phosphorylation in intracellular proteins of normal cells following contact with said CGs, a level of phosphorylation differing from that

detected in the normal cells indicating a high probability of abnormality in the tested cells, wherein said compound is as defined in claim 1.

38-43. (canceled)

44. (new) The compound of claim 1 of formula II



wherein X is H; Y is CH₂ or CHO_H; and R is H, a cation or phenyl.

45. (new) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, the compound of claim 44.

46. (new) A method for treatment of disorders and diseases which can be treated by phosphorylation of intracellular proteins comprising administering to the individual in need a therapeutically effective amount of a compound as defined in claim 44.